The efficacy and medication feedback of trametinib (Megenin) in patients with melanoma

Trametinib (Trametinib) is a MEK inhibitor, mainly used for the treatment of patients with BRAF mutation-positive advanced melanoma. Its mechanism of action is by inhibiting theRAS-RAF-MEK-ERK signaling pathway, thereby blocking the proliferation and survival signals of cancer cells to control tumor progression. Clinical studies have shown that trametinib, when used in combination with BRAF inhibitors, can significantly prolong the progression-free survival (PFS) and overall survival (OS) of patients, especially for patients who cannot be surgically resected or have metastasized.

In terms of actual efficacy, after patients use trametinib, some people can see signs of shrinkage of skin and lymph node lesions within a few weeks to two months. Clinical feedback shows that when trametinib is used alone or in combination with dabrafenib, the objective response rate (ORR) can reach 30% to pan>50%, and the progression-free survival is usually around 9 to 11 months. For some patients, the efficacy is obvious and long-lasting, but regular imaging follow-up is still needed to evaluate the tumor response.

Regarding the medication experience, most patients reported that trametinib is convenient to take orally, but may cause side effects such as rash, diarrhea, fatigue, and increased blood pressure. Some patients require dose adjustment, auxiliary medications, or lifestyle management to alleviate adverse effects. Doctors usually closely monitor blood pressure, blood routine and liver function in the early stages of treatment to ensure patient safety and respond to adverse reactions in a timely manner.

Overall, trametinib has clear efficacy in BRAF mutation-positive melanoma patients and can improve the quality of life of some advanced patients. However, the efficacy varies between individuals, and some patients may develop drug resistance or disease progression. Therefore, patients need to follow the doctor's instructions for regular review during use, maintain communication with the doctor, and adjust the treatment plan in a timely manner to obtain the best efficacy and safety.

Reference materials:https://www.drugs.com/